- See: Osteoporosis
- for most postmenopausal women with osteoporosis, estrogen therapy also should be instituted at a dose of 0.625 mg of conjugated estrogen per day or its equivalent;
- administration of estrogen by transdermal patch is effective and may result in more stable plasma estrogen concentrations;
- at menopause, bone turnover increases, w/ greater increase in bone resorption than in bone formation;
- accelerated bone loss that results diminishes exponentially with time;
- most bone is lost during the first 3 to 6 years after menopause, but some loss related to low estrogen levels may continue for up to 20 years;
- if begun soon after menopause, estrogen therapy prevents early phase of bone loss and decreases the incidence of subsequent osteoporosis related fractures by about 50 percent;
- in women with established osteoporosis, estrogen therapy is still effective;
- there is a reduction in hip and wrist frx in women whose estrogen replacement was begun within a few years of menopause;
- even when started as late as 6 years after menopause, estrogen replacement prevents further loss of bone mass but does not restore it to premenopausal levels;
- there is no convincing evidence that estrogen benefits women over the age of 75 years;
- Estrogen Protocol for Osteoporosis:
#1 (for women w/ a uterus w/o vaginal withdrawl bleeding - 60%)
- Premarin 0.625 mg PO qd
- Provera 2.5 mg PO qd
#2 (for women w/ a uterus and w/ withdrawl bleeding - 40%)
- Premarin 0.625 mg PO qd for 20 days.
- Provera 10 mg PO qd 10 days.
#3 (for women w/o a uterus)
- Premarin 0.625 mg PO qd for 25 days.
- then nothing for 5 days.
Effects of estrogen deficiency on the growth of tissue into porous titanium implants.